Page last updated: 2024-08-17

quinoxalines and mk 2206

quinoxalines has been researched along with mk 2206 in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Ahmed, O; Cohen, EE; Kuo, WL; Lingen, MW; Liu, J; Macleod, KF; Nagilla, M; Sharifi, MN1
Cong, L; Xia, ZK; Yang, RY1
Barata, JT; Bertaina, A; Buontempo, F; Cappellini, A; Chiarini, F; Evangelisti, C; Fragoso, R; Locatelli, F; Lonetti, A; Manzoli, L; Martelli, AM; Neri, LM; Oliveira, M; Orsini, E; Pession, A; Simioni, C1
Haniuda, M; Hosokawa, Y; Hyodo, T; Karnan, S; Konishi, H; Ota, A; Tsuzuki, S; Wahiduzzaman, M; Yamaji, M1
Bjune, K; Naderi, S; Wierød, L1
Bowen, JP; Güner, OF; Matesic, DF; Uko, NE1
Chuang, SJ; Hussain, N; Johanns, M; Kemp, BE; Rider, MH; Steinberg, GR; Vertommen, D1

Reviews

1 review(s) available for quinoxalines and mk 2206

ArticleYear
Akt Pathway Inhibitors.
    Current topics in medicinal chemistry, 2020, Volume: 20, Issue:10

    Topics: Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Diamines; Drug Design; Heterocyclic Compounds, 3-Ring; Humans; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Phospholipids; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Signal Transduction; Structure-Activity Relationship; Sulfonamides; Thiadiazoles; Thiophenes

2020

Other Studies

6 other study(ies) available for quinoxalines and mk 2206

ArticleYear
p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Gene Expression; Heterocyclic Compounds, 3-Ring; Humans; Mouth Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Sequestosome-1 Protein; Sulfonamides; Tissue Array Analysis; Ubiquitin-Activating Enzymes

2014
Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy.
    Archiv der Pharmazie, 2014, Volume: 347, Issue:9

    Topics: Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Molecular Targeted Therapy; Morpholines; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Quinolines; Quinoxalines; Receptors, Transforming Growth Factor beta; Scleroderma, Systemic

2014
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
    Journal of cellular physiology, 2018, Volume: 233, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Child; Child, Preschool; Class I Phosphatidylinositol 3-Kinases; Dexamethasone; Glucocorticoids; Heterocyclic Compounds, 3-Ring; Humans; Isoquinolines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Purines; Quinazolinones; Quinoxalines; Thiazolidinediones; Triazines

2018
Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
    Cancer medicine, 2017, Volume: 6, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Caspase 3; Caspase 7; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Forkhead Box Protein O1; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Inhibitory Concentration 50; Mesothelioma; Oxadiazoles; Phosphorylation; Phosphorylcholine; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinoxalines; Sulfonamides; Thiadiazoles; Thiophenes

2017
Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms.
    PloS one, 2019, Volume: 14, Issue:6

    Topics: Aminopyridines; Animals; Benzimidazoles; CHO Cells; Cricetinae; Cricetulus; Hep G2 Cells; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Phosphorylcholine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptors, LDL; Ribonucleosides; RNA Stability; RNA, Messenger; Transcriptional Activation

2019
Effects of PKB/Akt inhibitors on insulin-stimulated lipogenesis and phosphorylation state of lipogenic enzymes in white adipose tissue.
    The Biochemical journal, 2020, 04-30, Volume: 477, Issue:8

    Topics: Acetyl-CoA Carboxylase; Adipocytes; Adipose Tissue, White; Animals; Benzylamines; Heterocyclic Compounds, 3-Ring; Insulin; Lipogenesis; Male; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Rats; Rats, Wistar

2020